Novel regulatory role for Kaposi's sarcoma-associated herpesvirus-encoded vFLIP in chemosensitization to bleomycin

Biochemical and Biophysical Research Communications

Volumn 415, Issue 2, 2011, Pages 305-312

  Masuda, Yuri ^a   Noguchi, Kohji ^a   Segawa, Hatsune ^a   Tanaka, Noritaka ^a   Katayama, Kazuhiro ^a   Mitsuhashi, Junko ^a   Sugimoto, Yoshikazu ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Anticancer drug; Bleomycin; Chemotherapy; KSHV; NF B; VFLIP

Indexed keywords

BLEOMYCIN; CHECKPOINT KINASE 2; FLICE INHIBITORY PROTEIN; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RAD51 PROTEIN;

ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DNA DAMAGE CHECKPOINT; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; M PHASE CELL CYCLE CHECKPOINT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CELL DIVISION; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION; HEK293 CELLS; HISTONES; HUMANS; PHOSPHOPROTEIN PHOSPHATASES; VIRAL PROTEINS;

HUMAN HERPESVIRUS 8;

EID: 84855886078     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.050     Document Type: Article

References (24)

1. Boshoff C., Chang Y. Kaposi's sarcoma-associated herpesvirus: a new DNA tumor virus. Annu. Rev. Med. 2001, 52:453-470.
2. Noguchi K., Fukazawa H., Murakami Y., Takahashi N., Yamagoe S., Uehara Y. Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies. Cancer Sci. 2007, 98:1288-1296.
3. Field N., Low W., Daniels M., Howell S., Daviet L., Boshoff C., Collins M. KSHV vFLIP binds to IKK-gamma to activate IKK. J. Cell Sci. 2003, 116:3721-3728.
4. Bagneris C., Ageichik A.V., Cronin N., Wallace B., Collins M., Boshoff C., Waksman G., Barrett T. Crystal structure of a vFlip-IKKgamma complex: insights into viral activation of the IKK signalosome. Mol. Cell 2008, 30:620-631.
5. Guasparri I., Keller S.A., Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 2004, 199:993-1003.
6. Ballon G., Chen K., Perez R., Tam W., Cesarman E. Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J. Clin. Invest. 2011, 121:1141-1153.
7. Sakakibara S., Pise-Masison C.A., Brady J.N., Tosato G. Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells. J. Virol. 2009, 83:2140-2153.
8. Spano J.P., Costagliola D., Katlama C., Mounier N., Oksenhendler E., Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J. Clin. Oncol. 2008, 26:4834-4842.
9. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40.
10. Yoshioka H., Noguchi K., Katayama K., Mitsuhashi J., Yamagoe S., Fujimuro M., Sugimoto Y. Functional availability of gamma-herpesvirus K-cyclin is regulated by cellular CDK6 and p16INK4a. Biochem. Biophys. Res. Commun. 2010, 394:1000-1005.
11. Luo J.L., Kamata H., Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 2005, 115:2625-2632.
12. Chen J., Stubbe J. Bleomycins: towards better therapeutics. Nat. Rev. Cancer 2005, 5:102-112.
13. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73:39-85.
14. Bekker-Jensen S., Lukas C., Kitagawa R., Melander F., Kastan M.B., Bartek J., Lukas J. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol. 2006, 173:195-206.
15. Kinner A., Wu W., Staudt C., Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008, 36:5678-5694.
16. Rossi M., Demidov O.N., Anderson C.W., Appella E., Mazur S.J. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic Acids Res. 2008, 36:7168-7180.
17. Chew J., Biswas S., Shreeram S., Humaidi M., Wong E.T., Dhillion M.K., Teo H., Hazra A., Fang C.C., Lopez-Collazo E., Bulavin D.V., Tergaonkar V. WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat. Cell Biol. 2009, 11:659-666.
18. Cha H., Lowe J.M., Li H., Lee J.S., Belova G.I., Bulavin D.V., Fornace A.J. Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response. Cancer Res. 2010, 70:4112-4122.
19. Macurek L., Lindqvist A., Voets O., Kool J., Vos H.R., Medema R.H. Wip1 phosphatase is associated with chromatin and dephosphorylates gammaH2AX to promote checkpoint inhibition. Oncogene 2010, 29:2281-2291.
20. Moon S.H., Lin L., Zhang X., Nguyen T.A., Darlington Y., Waldman A.S., Lu X., Donehower L.A. Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair. J. Biol. Chem. 2010, 285:12935-12947.
21. Lindqvist A., de Bruijn M., Macurek L., Bras A., Mensinga A., Bruinsma W., Voets O., Kranenburg O., Medema R.H. Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression. EMBO J. 2009, 28:3196-3206.
22. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell 2004, 13:853-865.
23. McGarvey M.E., Tulpule A., Cai J., Zheng T., Masood R., Espina B., Arora N., Smith D.L., Gill P.S. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr. Opin. Oncol. 1998, 10:413-421.
24. Simonelli C., Tedeschi R., Gloghini A., Talamini R., Bortolin M.T., Berretta M., Spina M., Morassut S., Vaccher E., De Paoli P., Carbone A., Tirelli U. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J. Med. Virol. 2009, 81:888-896.